Zobrazeno 1 - 10
of 15
pro vyhledávání: '"Yoichiro, Ogama"'
Autor:
Miwa Haranaka, James Baber, Yoichiro Ogama, Masako Yamaji, Masakazu Aizawa, Osamu Kogawara, Ingrid Scully, Eleni Lagkadinou, Ӧzlem Türeci, Uğur Şahin, Philip R. Dormitzer, William C. Gruber, Stephen Lockhart
Publikováno v:
Nature Communications, Vol 12, Iss 1, Pp 1-7 (2021)
Here the authors provide the interim analysis of an ongoing phase 1/2 study of the BNT162b2 vaccine in healthy Japanese adults. They report mainly mild to moderate local reactions and no serious adverse events as well as good antibody induction one m
Externí odkaz:
https://doaj.org/article/b46c9a1d119e4f05b2b58be147b5baa4
Autor:
Naoto Noda, Takeshi Takagaki, Yasuhide Yodo, Yuzo Horibuchi, Shuichi Iino, Shunji Matsuki, Yoichiro Ogama, Hiroyoshi Kakuyama
Publikováno v:
Pharmacology Research & Perspectives, Vol 9, Iss 5, Pp n/a-n/a (2021)
Abstract This study examined the safety, tolerability, and pharmacokinetics (PK) of napabucasin in healthy Asian and non‐Asian participants and investigated the potential for QT/QTc interval prolongation. This five‐part (A–E) study proceeded in
Externí odkaz:
https://doaj.org/article/b804592a5ce74d749d7cb7315b7cacf7
Autor:
Miwa Haranaka, Takanori Tanaka, SungHyun Kim, YunJu Bae, DaBee Jeon, EunJin Choi, JungBin Cha, SangMi Lee, Yoichiro Ogama
Publikováno v:
Immunotherapy. 15:149-161
Aim: Comparing pharmacokinetics and safety of CT-P17 and EU-approved reference adalimumab (EU–adalimumab) in Japan. Materials & methods: Double-blind, parallel-group phase I trial at three hospitals. Healthy Japanese adults were randomized (1:1) to
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::0602f1d85a8c0f20ae02fefa71d699d4
https://doi.org/10.2217/imt-2022-0181
https://doi.org/10.2217/imt-2022-0181
Autor:
Yoichiro Ogama, Yuji Kumagai, Norio Komatsu, Marito Araki, Nami Masubuchi, Hiroko Akiyoshi, Tadashi Matsuura, Hiromi Kirisako, Akiko Kyoya, Fumiko Nomura, Yuta Ohira, Takuya Yokokawa, Yukiya Yamamoto
Publikováno v:
Clinical Pharmacology in Drug Development.
This study aimed to evaluate the safety, pharmacokinetics, and pharmacodynamics of PPMX-T003, a novel human monoclonal antibody for transferrin receptor 1 (TFR1), in healthy individuals. Forty participants were enrolled and randomized to PPMX-T003 do
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ade23bbb1a4590983fdea761a650455a
https://doi.org/10.1002/cpdd.1216
https://doi.org/10.1002/cpdd.1216
Autor:
Naoto Noda, Tatsuto Hamatani, Yuta Shibue, Takeshi Takagaki, Atsushi Kitamura, Miwa Haranaka, Yoichiro Ogama, Hiroyoshi Kakuyama
Publikováno v:
Clinical pharmacology in drug developmentReferences. 11(10)
EPI-589 attenuates oxidative stress due to the radical scavenging activity of the reduced form and affects mitochondrial energy metabolism as a substrate of quinone-oxidoreductases. Given the effects of EPI-589 on oxidative stress and mitochondrial d
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::06f73994aa72926a7600e5cd1ba49d77
https://pubmed.ncbi.nlm.nih.gov/35988057
https://pubmed.ncbi.nlm.nih.gov/35988057
Autor:
Takeshi Takagaki, Yasuhide Yodo, Naoto Noda, Yoichiro Ogama, Yuzo Horibuchi, Shunji Matsuki, Hiroyoshi Kakuyama, Shuichi Iino
Publikováno v:
Pharmacology Research & Perspectives, Vol 9, Iss 5, Pp n/a-n/a (2021)
Pharmacology Research & Perspectives
Pharmacology Research & Perspectives
This study examined the safety, tolerability, and pharmacokinetics (PK) of napabucasin in healthy Asian and non‐Asian participants and investigated the potential for QT/QTc interval prolongation. This five‐part (A–E) study proceeded in a stepwi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0c4089adcc90d75b60acbf7742d0203d
https://doaj.org/article/b804592a5ce74d749d7cb7315b7cacf7
https://doaj.org/article/b804592a5ce74d749d7cb7315b7cacf7
Autor:
Yoichiro Ogama, Nahoko Kasahara-Ito, Yuji Kumagai, Hiroyuki Fukase, Yasuki Takano, Tomohisa Saito, Kimio Terao, Yasuhiro Ohba, Noboru Nakamichi, Tomoko Ichihara, Sachiya Ikeda, Sumire Shimada
Publikováno v:
Drug Research. 67:349-357
Tofogliflozin is a selective oral inhibitor of sodium-glucose co-transporter 2 for treatment of type 2 diabetes mellitus. The pharmacokinetics, pharmacodynamics, and safety of tofogliflozin were investigated in healthy male subjects. Three studies we
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9c959da383736eb7ee592228f37c3db3
https://doi.org/10.1055/s-0043-104779
https://doi.org/10.1055/s-0043-104779
Autor:
Asuka Yamamoto, Taro Amagasaki, Kazuto Natsume, Margaret M. Woo, Yoichiro Ogama, Tomoko Mineyama, Naomi Shimada
Publikováno v:
International Journal of Hematology. 97:351-359
Ruxolitinib (INC424), a potent and selective oral Janus kinase 1 and 2 inhibitor, was recently approved by the US food and drug administration for the treatment of intermediate or high-risk myelofibrosis. The safety, tolerability, and pharmacokinetic
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::845ecb39debf2e87eb7d8d685ed68c5e
https://doi.org/10.1007/s12185-013-1280-5
https://doi.org/10.1007/s12185-013-1280-5
Autor:
Takashi Kano, Takaaki Nagami, Midori Yokoyama, Ikumi Tamai, Kozue Kishimura, Rieko Shimada, Takuo Ogihara, Nao Kodama, Akihiro Inano, Kaori Morimoto, Shinya Toda, Yoichiro Ogama, Takeshi Chiyoda
Publikováno v:
Journal of Pharmaceutical Sciences. 100:3854-3861
We previously showed that oseltamivir, a prodrug of the influenza virus neuraminidase inhibitor Ro 64-0802, is a substrate of proton-coupled oligopeptide transporter (PEPT1), and its intestinal absorption in rats is markedly inhibited by administrati
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::191f4120f0e9d65e6c58ed6241b8451c
https://doi.org/10.1002/jps.22627
https://doi.org/10.1002/jps.22627
Autor:
Mitsune Tanimoto, Mamoru Ouchida, Toshiyuki Watanabe, Nobuharu Fujii, Kozo Masuda, Kenji Shimizu, Kosei Matsue, Yoichiro Ogama, Kazuma Ikeda, Motoyuki Tanaka, Akio Hiraki
Publikováno v:
Cancer Science. 98:102-108
Loss or down-regulation of human leukocyte antigen (HLA) class I expression has been demonstrated in a variety of solid tumors. To date, such altered HLA expression has not been studied extensively in freshly isolated leukemic blasts. If it occurs, l
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9e6cece6bba3e41d661e9d17a00f0a6a
https://doi.org/10.1111/j.1349-7006.2006.00356.x
https://doi.org/10.1111/j.1349-7006.2006.00356.x